Prevalence and Risk Factors of Hepatitis C Virus Antibodies among Inmates in North Central Nigeria: A Cross-Sectional Study
DOI:
https://doi.org/10.47430/ujmr.2492.008Keywords:
Anti-HCV-Ab, Hepatitis C virus, Prevalence, Risk Factors, IncarcerationAbstract
Study’s Novelty/Excerpt
- This study investigates the prevalence of anti-hepatitis C virus antibodies among adult inmates in north-central Nigeria, a population previously underrepresented in hepatitis C research.
- It employs the Aria HCV Ab PLUS COMBO Rapid Test cassette, providing highly sensitive and specific screening results, and reveals a significant prevalence of 7.27%, highlighting a substantial public health concern in correctional facilities.
- Furthermore, the study emphasize the need to review and enhance current screening, preventive measures, and understanding of transmission routes in low- and middle-income countries, advocating for targeted public health interventions.
Full Abstract
Hepatitis C is a serious global health concern, with an estimated 189 million cases and 71 million chronic carriers. The lack of data among certain populations in low- and middle-income nations like Nigeria exacerbates the dilemma. The purpose of this research is to ascertain the prevalence of anti-hepatitis C virus antibodies in adult inmates in north-central Nigeria. In this cross-sectional survey, 385 adult inmates (age 18 years and above) were enrolled from three selected correctional facilities in North Central Nigeria. Each volunteer gave their informed consent before blood sample collection. An interviewer-administered questionnaire was administered to the consented 385 inmates. A venous blood sample (5mL) was collected from each inmate and tested for the presence of HCV antibody. Aria HCV Ab PLUS COMBO Rapid Test cassette, which is a lateral flow chromatographic immunoassay, was used to screen the samples for anti-HCV antibodies. The sensitivity and specificity of the test are 98.7% and 99.6%, respectively, while the overall Agreement is 99.3%. The screening is performed according to the manufacturer’s instructions. The mean age of the participants was 33.92 years. The prevalence of anti-HCV antibodies was 7.27%, indicating a significant health concern among inmates. These findings suggest the need for enhanced screening and preventive measures in correctional facilities. The bivariate analyses of risk factors associated with the transmission of hepatitis c virus infection showed no statistical significance. The high prevalence (7.27%) of anti-HCV antibodies among the inmates calls for serious and urgent public health intervention through enhanced screening and public education. The documented risk factors associated with transmission of hepatitis c virus need to be reviewed, particularly in low- and middle-income countries, as there may be other possible routes of hepatitis c virus transmission other than parenteral.
Downloads
References
Behzadifar, M., Abolghasem Gorji, H., Rezapour, A., & Bragazzi, N. (2018). Prevalence of hepatitis C virus infection among prisoners in Iran: A systematic review and meta-analysis. Harm Reduction Journal, 15. https://doi.org/10.1186/s12954-018-0231-0
Daniels, A. M., & Studdert, D. M. (2020). Hepatitis C Treatment in Prisons—Incarcerated People’s Uncertain Right to Direct-Acting Antiviral Therapy. The New England Journal of Medicine, 383(7), 611–613. https://doi.org/10.1056/NEJMp2004438
Dan-Nwafor, C., Adeoye, I., Aderemi, K., Adebobola, B., Nguku, P., Ade-Yusuf, I., & Udom, E. (2018). Knowledge, Serological Markers and Risk Factors associated with Hepatitis B and C Virus Infection among Kuje Prison Inmates, Federal Capital Territory, Nigeria. International Journal of Infectious Diseases, 73, 374. https://doi.org/10.1016/j.ijid.2018.04.4260
Falla, A. M., Ahmad, A. A., Duffell, E., Noori, T., & Veldhuijzen, I. K. (2018). Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: A focus on migrants from anti-HCV endemic countries. BMC Infectious Diseases, 18(1). https://doi.org/10.1186/s12879-017-2908-5
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 61(1), S45–S57.
https://doi.org/10.1016/j.jhep.2014.07.027
Huang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022). Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism, 34(7), 969-977.e2.
https://doi.org/10.1016/j.cmet.2022.05.003
Jack, K., Linsley, P., Thomson, B. J., & Irving, W. L. (2020). How do people in prison feel about opt‐out hepatitis C virus testing? Journal of Viral Hepatitis, 27(10), 1003–1011.
https://doi.org/10.1111/jvh.13338
Kamarulzaman, A., Verster, A., & Altice, F. L. (2019). Prisons: Ignore them at our peril. Current Opinion in HIV and AIDS, 14(5), 415–422.
https://doi.org/10.1097/COH.0000000000000572
Midgard, H., Weir, A., Palmateer, N., Lo Re, V., Pineda, J. A., Macías, J., & Dalgard, O. (2016). HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology, 65(1), S33–S45. https://doi.org/10.1016/j.jhep.2016.07.012
Moazen, B., Stöver, H., Dolan, K., Jahn, A., & Neuhann, F. (2020). Prisoners should not be left behind in HCV research and policies. Harm Reduction Journal, 17(1), 1–2.
https://doi.org/10.1186/s12954-020-00379-y
Okafor, I. M., Ugwu, S. O., & Okoroiwu, H. U. (2020). Hepatitis C virus infection and its associated factors among prisoners in a Nigerian prison. BMC Gastroenterology, 20(1), 1–9.
https://doi.org/10.1186/s12876-020-01504-8
Onyekwere, C. A., O Ogbera, A., Olusola Dada, A., O Adeleye, O., O Dosunmu, A., Akinbami, A. A., Osikomaiya, B., & Hameed, O. (2016). Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors: A Report From a Tertiary Hospital. Hepatitis Monthly, 16(5).
https://doi.org/10.5812/hepatmon.35532
Oru, E., & Verster, A. (2019). Access to hepatitis C care for people who inject drugs and people in prisons. The Lancet Gastroenterology and Hepatology, 4(9), 662–663.
https://doi.org/10.1016/S2468-1253(19)30201-8
Rao, V. B., Johari, N., du Cros, P., Messina, J., Ford, N., & Cooke, G. S. (2015). Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: A systematic review and meta-analysis. The Lancet Infectious Diseases, 15(7), 819–824.
https://doi.org/10.1016/S1473-3099(15)00006-7
SeyedAlinaghi, S., Farhoudi, B., Shahmohamadi, E., Rasoolinejad, M., Hasannezhad, M., Rashidi, M. R., Dadras, O., Moradi, A., Parmoon, Z., Ebrahimi, H., & Asadollahi-Amin, A. (2023). Prevalence of and risk factors for HCV among incarcerated people at Great Tehran Prison: A cross-sectional study. International Journal of Prisoner Health, ahead-of-print(ahead-of-print).
https://doi.org/10.1108/IJPH-09-2022-0059
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019). Hepatitis C. Lancet (London, England), 394(10207), 1451–1466.
https://doi.org/10.1016/S0140-6736(19)32320-7
Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N., Cowie, B., Forouzanfour, M. H., Groeger, J., Hanafiah, K. M., Jacobsen, K. H., James, S. L., MacLachlan, J., Malekzadeh, R., Martin, N. K., Mokdad, A. A., … Cooke, G. S. (2016). The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. The Lancet, 388(10049), 1081–1088. https://doi.org/10.1016/S0140-6736(16)30579-7
World Health Organization & Global Hepatitis Programme. (2017). WHO guidelines on hepatitis B and C testing. http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anthony Tiri John, Murna Ali, Hashimu Zakari, Joseph Anejo-Okopi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
